<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03193801</url>
  </required_header>
  <id_info>
    <org_study_id>2015-08 MVIV</org_study_id>
    <nct_id>NCT03193801</nct_id>
  </id_info>
  <brief_title>PARTNER 3 Trial - Mitral Valve in Valve</brief_title>
  <official_title>PARTNER 3 Trial - Mitral Valve in Valve is a Prospective, Single-Arm, Multicenter Study to Investigate the Safety and Effectiveness of SAPIEN 3 Transcatheter Heart Valve Implantation in Patients With a Failing Mitral Bioprosthetic Valve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and effectiveness of the SAPIEN 3 (Edwards Lifesciences, Irvine,
      California) transcatheter heart valve in patients with a failing mitral bioprosthetic valve.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, single-arm, multicenter clinical trial. This study will enroll patients with
      symptomatic heart disease due to a failing bioprosthetic mitral valve (stenosed,
      insufficient, or combined).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Effectiveness - composite endpoint of all-cause mortality and stroke</measure>
    <time_frame>1 Year</time_frame>
    <description>Non-hierarchical composite endpoint of all-cause mortality and stroke at 1 year post procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) Functional Class</measure>
    <time_frame>30 Days</time_frame>
    <description>NYHA is a functional classification of heart failure based on how much a patient is limited during physical activity. The rating ranges from I - IV, with the lowest (I) as no limitations and the highest (IV) unable to carry on any physical activity without discomfort.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Mitral Valve Insufficiency</condition>
  <condition>Mitral Valve Disease</condition>
  <condition>Mitral Valve Regurgitation</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Failing mitral transcatheter valve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a failing bioprosthetic valve in the mitral position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN 3 transcatheter valve.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Edwards SAPIEN 3 transcatheter valve, Model 9600TFX</intervention_name>
    <description>Edwards SAPIEN 3 THV system Model 9600TFX with the associated delivery systems.</description>
    <arm_group_label>Failing mitral transcatheter valve</arm_group_label>
    <other_name>TMVR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Failing surgically implanted bioprosthetic valve in the mitral position demonstrating
             ≥ moderate stenosis and/or ≥ moderate insufficiency.

          2. NYHA Functional Class ≥ II.

          3. Heart Team agrees that the patient is at intermediate surgical risk.

          4. Heart Team agrees valve implantation will likely benefit the patient.

          5. The study patient has been informed of the nature of the study, agrees to its
             provisions and has provided written informed consent as approved by the Institutional
             Review Board (IRB) of the respective clinical site.

        Exclusion Criteria:

          1. Index valve has ≥ mild paravalvular regurgitation where the surgical bioprosthesis is
             not securely fixed in the native annulus or is not structurally intact as determined
             by transesophageal echocardiography (TEE).

          2. Aortomitral angle &lt;105°.

          3. Severe regurgitation or stenosis of any other valve.

          4. Severe right ventricle (RV) dysfunction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Justine Encabo</last_name>
    <phone>949-250-3502</phone>
    <email>Justine_Encabo@edwards.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vinny Podichetty, MD</last_name>
    <phone>949-250-5794</phone>
    <email>Vinny_Podichetty@edwards.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Hill</last_name>
      <phone>313-916-7430</phone>
      <email>Ahill13@hfhs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Heart Hospital of Baylor Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Necole Kell</last_name>
      <phone>469-814-4871</phone>
      <email>Necole.Kell@BSWHealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2017</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SAPIEN 3</keyword>
  <keyword>PARTNER 3</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>TMVR</keyword>
  <keyword>failing valve</keyword>
  <keyword>failing bioprosthetic valve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

